Advanced cardiovascular and metabolic services will be provided to biopharm by a strategic collaboration between CROs Cardialysis and Sticares InterACT.
The world’s biggest drugmaker, Pfizer, is set to bulk up its collaborative research partnerships with CROs and academics in Asia to lower costs and produce more affordable drugs.
GlaxoSmithKline (GSK) has entered into two unrelated development deals by signing license agreements for Delphi Genetics’ StabyExpress for its vaccine production operations and OncoMethylome Sciences’ DNA methylation specific PCR biomarkers for its cancer...
India’s Sun Pharma has finally acquired a controlling stake in Israeli generics firm Taro Pharmaceutical Industries, significantly expanding its manufacturing capacity in North America.
Trials initiated in CEE and Russia fell 18 per cent year-on-year in 2009, ending a period of growth. Outsourcing-Pharma presents this rise and fall as an interactive visualisation.
Worrying times lie ahead for Pfizer’s advertiser, Aegis Group’s Carat, as the drug giant has decided to review its $1.3bn media account, as the firm is speculated to be slashing its outgoings.
Intelsius, formerly DGP Group, has introduced Orcatherm to address the increasing pharma industry need for temperature-controlled packaging and regulatory compliant sample transport solutions.
The US FDA’s risk evaluation mitigation strategy (REMS) can be a challenge for pharmaceutical companies unfamiliar with the process according to PPD’s executive director of risk management Frank Gallo.
SOCMA CEO predicts reintroduction of rejected permanent R&D tax credit plan and urges Congress to act “sooner rather than later” to support US manufacturers.
The US FTC has given a positive advisory opinion to Rx-360’s shared audits and said the programme appears to offer “cognisable cost-saving and safety enhancing features”.
In an exclusive Q&A Mark Rohlfing, Almac’s director of Quality, updates Outsourcing-pharma on the firm’s new North American HQ, growth plans and US recruitment drive.
Rexam and Med Time Technology, a US manufacturer of plastic prescription vials, have launched “Pill Timer,” a packaging solution designed to boost treatment compliance rates.
Addressing the drug industry's need to demonstrate value to stakeholders presents a significant opportunity for service providers, according to Jim Featherstone, VP of Quintiles' commercial arm.
Creation of large datasets for use in comparative effectiveness research and other fields could be limited by privacy modifications to the HITECH act, according to ACRO.
Clinical data management is, and will continue to be a key concern for the pharmaceutical industry, according to Susan Bornstein, executive vice president of eClinical solutions, who discussed the issue with Outsourcing-pharma earlier this week.
Delays during IRB review are a growing concern in the trials sector according to Christine Grady of the US National Institutes of Health’s (NIH) department of Bioethics.
Indian drugmaker Cipla may invest in South Africa’s Cipla Medpro to boost manufacturing capacity and improve access to rapidly expanding African pharmaceutical markets.
Patient recruiters and national regulators must learn from each other to better understand outreach tactics and how they fit with a country’s ethics and laws.
Retention strategies, trial site evaluations and dedicated budgets should be used to recruit patients to, and keep them in, clinical trials, according to research.
Syringe maker Unilife said it was hit by falling revenues, costs of US relocation and workforce expansion in Q4, but that significant business progress was made in fiscal 2010.
ZRG Partners says there was a “fight for talent” in hiring, firing and vacancies in Q2, with the outsourcing and pharmaceutical sectors battling for employees within regulatory, quality and clinical roles.
Aterovax has teamed up with Biomnis to target the clinical trial industry with a new atherosclerosis biomarker, sPLA2, designed to give researchers better insight into a candidate heart drug’s therapeutic potential.
Almac says an effective biomarker strategy boosts a drug candidates’ chance of success and can ultimately add value to a developer’s business by opening door to diagnostics.
